We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Acetarsol Suppositories: Effective Treatment for Refractory Proctitis in a Cohort of Patients with Inflammatory Bowel Disease.
- Authors
Kiely, Christopher J.; Clark, Angela; Bhattacharyya, Joya; Moran, Gordon W.; Lee, James C.; Parkes, Miles
- Abstract
<bold>Background: </bold>Management of proctitis refractory to conventional therapies presents a common clinical problem. The use of acetarsol suppositories, which are derived from organic arsenic, was first described in 1965. Data concerning clinical efficacy and tolerability are very limited.<bold>Aim: </bold>To examine the efficacy of acetarsol suppositories for the treatment of refractory proctitis.<bold>Methods: </bold>A retrospective analysis was performed on patients with inflammatory bowel disease treated with acetarsol suppositories between 2008 and 2014 at Addenbrooke's Hospital, Cambridge, United Kingdom. Clinical response was defined as resolution of symptoms back to baseline at the time of next clinic review.<bold>Results: </bold>Thirty-nine patients were prescribed acetarsol suppositories between March 2008 and July 2014 (29 patients with ulcerative colitis, nine with Crohn's disease, and one with indeterminate colitis). Thirty-eight were included for analysis. The standard dose of acetarsol was 250 mg twice daily per rectum for 4 weeks. Clinical response was observed in 26 patients (68%). Of the 11 patients who had endoscopic assessment before and after treatment, nine (82%) showed endoscopic improvement and five (45%) were in complete remission (Wilcoxon signed-rank test p = 0.006). One patient developed a macular skin rash 1 week after commencing acetarsol, which resolved within 4 weeks of drug cessation.<bold>Conclusion: </bold>Acetarsol was effective for two out of every three patients with refractory proctitis. This cohort had failed a broad range of topical and systemic treatments, including anti-TNFα therapy. Clinical efficacy was reflected in significant endoscopic improvement. Adverse effects of acetarsol were rare.
- Subjects
PROCTITIS; INFLAMMATORY bowel disease treatment; TUMOR necrosis factors; SYMPTOMS; TREATMENT effectiveness; ENDOSCOPIC surgery; THERAPEUTICS; ANTI-infective agents; ARSENIC compounds; COMPARATIVE studies; INFLAMMATORY bowel diseases; RESEARCH methodology; MEDICAL cooperation; RECTAL diseases; RESEARCH; RESEARCH funding; SUPPOSITORIES; EVALUATION research; RETROSPECTIVE studies; DISEASE complications
- Publication
Digestive Diseases & Sciences, 2018, Vol 63, Issue 4, p1011
- ISSN
0163-2116
- Publication type
journal article
- DOI
10.1007/s10620-017-4890-6